Avalo Therapeutics CMO exercises options, sells shares

Avalo Therapeutics Chief Medical Officer Mittie Doyle exercised 1,000 stock options on July 27, 2026 at an exercise price of $12.65 per share, receiving 1,000 shares of common stock, then sold 1,000 shares at $20.00 per share the same day.

Rhea-AI Filing Summary

Avalo Therapeutics Chief Medical Officer Mittie Doyle exercised 1,000 stock options on July 27, 2026 at an exercise price of $12.65 per share, receiving 1,000 shares of common stock, then sold 1,000 shares at $20.00 per share the same day. After the exercise, Doyle holds 124,750 stock options at $12.65 expiring July 15, 2034. All transactions were carried out under a Rule 10b5-1 trading plan adopted on November 13, 2025.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,000 shares ($7K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Doyle Mittie

Role Chief Medical Officer

Sold 1,000 shs ($20K)

Approx. gross sale proceeds $20K

Approx. exercise cost $13K

Approx. pre-tax spread $7K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F2	1,000	$0.00	$0.00
Exercise	Common Stock F1	1,000	$12.65	$13K
Sale	Common Stock F1	1,000	$20.00	$20K

Holdings After Transaction: Stock Option (Right to Buy) — 124,750 contracts (Direct); Common Stock — 51,776 shares (Direct)

Footnotes (2)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
2. F2. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Options exercised: 1,000 shares Exercise price: $12.65 per share Shares sold: 1,000 shares +4 more

7 metrics

Options exercised 1,000 shares Stock options exercised on 2026-07-27 at $12.65 per share

Exercise price $12.65 per share Exercise or conversion of derivative security on 2026-07-27

Shares sold 1,000 shares Common stock sold on 2026-07-27 at $20.00 per share

Sale price $20.00 per share Open-market or private sale of common stock on 2026-07-27

Remaining options 124,750 options Stock options outstanding after the reported exercise at $12.65

Option expiration 2034-07-15 Expiration date of the stock option award exercised in part

10b5-1 plan adoption date November 13, 2025 Date Mittie Doyle adopted the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), Exercise or conversion of derivative security

3 terms

Rule 10b5-1 trading plan regulatory

"The transactions were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title is listed as Stock Option (Right to Buy) for the derivative"

Exercise or conversion of derivative security financial

"transaction_code_description states Exercise or conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Avalo Therapeutics (AVTX) report for Mittie Doyle?

Avalo Therapeutics reported that Chief Medical Officer Mittie Doyle exercised 1,000 stock options and sold 1,000 common shares on July 27, 2026. The exercise price was $12.65 per share and the sale price was $20.00 per share, executed the same day.

At what prices did Mittie Doyle exercise and sell Avalo Therapeutics (AVTX) shares?

Mittie Doyle exercised stock options for 1,000 shares at an exercise price of $12.65 per share and then sold 1,000 shares of Avalo Therapeutics common stock at $20.00 per share on July 27, 2026, under a pre-arranged trading plan.

How many Avalo Therapeutics (AVTX) stock options does Mittie Doyle still hold after this transaction?

After this reported transaction, Mittie Doyle holds 124,750 stock options with an exercise price of $12.65 per share. These remaining options are scheduled to expire on July 15, 2034, according to the option terms disclosed.

Were Mittie Doyle’s Avalo Therapeutics (AVTX) trades made under a Rule 10b5-1 plan?

Yes. All reported transactions were effected under a Rule 10b5-1 trading plan adopted by Mittie Doyle on November 13, 2025. Such pre-arranged plans allow insiders to schedule trades in advance, independent of later material nonpublic information.

What type of derivative security did Mittie Doyle exercise in Avalo Therapeutics (AVTX)?

Mittie Doyle exercised a Stock Option (Right to Buy) covering 1,000 underlying common shares of Avalo Therapeutics at an exercise price of $12.65 per share. The option is scheduled to expire on July 15, 2034, with remaining options still outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 04:05 PM Accepted by SEC EDGAR 07/29/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle Mittie

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		M(1)		1,000	A	$12.65	52,776	D
Common Stock	07/27/2026		S(1)		1,000	D	$20	51,776	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.65	07/27/2026		M(1)			1,000	(2)	07/15/2034	Common Stock	1,000	$0	124,750	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

2. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)